$3500 | Single User
$6000 | Enterprise License

Metastatic Liver Cancer - Market Review, Epidemiology And Market Forecast - 2029
[Published by First View Insight]

Published by First View Insight: 20 Dec 2019 | 241399 | In Stock
Related Topics: Cancer

Introduction

FirstView Market Insight Metastatic Liver Cancer - Market Review, Epidemiology And Market Forecast - 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights.The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 2018-2029.A liver metastasis is a cancerous tumor that has spread to the liver from a cancer that started in another place in the body. It’s also called secondary liver cancer. Primary liver cancer originates in the liver and most commonly affects individuals who have risk factors such as hepatitis or cirrhosis.

Most of the time, cancer in the liver is secondary, or metastatic.

The cancer cells found in a metastatic liver tumor are not liver cells. They are the cells from the part of the body where the primary cancer began (for example, cancerous breast, colon, or lung cells).

Other names for this condition include:

liver metastases

metastases to the liver

stage IV or advanced cancerOverview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology & Forecast

This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.

Market Size

This section of report will address the major issues, on the size and total addressable market share. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyze the commercial potential of the product as well as the disease/therapy area.

Market Trends & Unmet needs

This section of the report helps to understand the market trend and opportunities by analyzing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analyzing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

List of products

Cabometyx (Cabozantinib-S-Malate)

Cabozantinib-S-Malate.

Cyramza (Ramucirumab)

Keytruda (Pembrolizumab)

Lenvatinib Mesylate.

Lenvima (Lenvatinib Mesylate)

Nexavar (Sorafenib Tosylate)

Nivolumab.

Table of Contents
for Metastatic Liver Cancer - Market Review, Epidemiology And Market Forecast - 2029 [Published by First View Insight]

  • 1. Disease overview

    1.1. Types

    1.2. Pathophysiology

    1.3. Symptoms

    1.4. Etiology

    1.5. Risk Factor

    1.6. Diagnosis

    2. Treatment Landscape

    2.1. List of Marketed Drugs

    2.1.1. Drug 1

    2.1.1.1. Product Profile

    2.1.1.2. Regulatory Milestones

    2.1.1.3. Advantages & Disadvantages

    2.1.1.4. Safety and Efficacy

    2.1.1.5. Side effects

    2.1.1.6. Unmet Need

    2.1.1.7. SWOT Analysis

    2.1.2 Drug 2

    2.1.2.1. Product Profile

    2.1.2.2. Regulatory Milestones

    2.1.2.3. Advantages & Disadvantages

    2.1.2.4. Safety and Efficacy

    2.1.2.5. Side effects

    2.1.2.6. Unmet Need

    2.1.2.7. SWOT Analysis

    To be continued

    2.2. List of Late stage products

    2.2.1. Drug 1

    2.2.1.1. Product Profile

    2.2.1.2. Regulatory Milestones

    2.2.1.3. Advantages & Disadvantages

    2.2.1.4. Safety and Efficacy

    2.2.1.5. Side effects

    2.2.1.6. Unmet Need

    2.2.1.7. SWOT Analysis

    2.2.2 Drug 2

    2.2.2.1. Product Profile

    2.2.2.2. Regulatory Milestones

    2.2.2.3. Advantages & Disadvantages

    2.2.2.4. Safety and Efficacy

    2.2.2.5. Side effects

    2.2.2.6. Unmet Need

    2.2.2.7. SWOT Analysis

    To be continued

    2.3. List of mid stage products

    2.3.1. Drug 1

    2.3.1.1. Product Profile

    2.3.1.2. Regulatory Milestones

    2.3.1.3. Advantages & Disadvantages

    2.3.1.4. Safety and Efficacy

    2.3.1.5. Side effects

    2.3.1.6. Unmet Need

    2.3.1.7. SWOT Analysis

    2.3.2 Drug 2

    2.3.2.1. Product Profile

    2.3.2.3. Regulatory Milestones

    2.3.2.3. Advantages & Disadvantages

    2.3.2.4. Safety and Efficacy

    2.3.2.5. Side effects

    2.3.2.6. Unmet Need

    2.3.2.7. SWOT Analysis

    To be continued

    2.4. List of early stage products

    2.4.1. Drug 1

    2.4.1.1. Product Profile

    2.4.1.2. Regulatory Milestones

    2.4.1.3. Advantages & Disadvantages

    2.4.1.4. Safety and Efficacy

    2.4.1.5. Side effects

    2.4.1.6. Unmet Need

    2.4.1.7. SWOT Analysis

    2.4.2 Drug 1

    2.4.2.1. Product Profile

    2.4.2.4. Regulatory Milestones

    2.4.2.4. Advantages & Disadvantages

    2.4.2.4. Safety and Efficacy

    2.4.2.5. Side effects

    2.4.2.6. Unmet Need

    2.4.2.7. SWOT Analysis

    To be continued

    3. Patent Information

    3.1. Patent Expiry in United States (US)

    3.2. Patent Expiry in European Union (EU)

    3.3. Patent Expiry in Japan

    4. Historical and Forecasted sales of marketed drugs

    5. Global Epidemiology - Forecasted to 2029

    6. Current Epidemiology - Forecasted to 2029 by 7 Major Markets (7MM)

    6.1. Epidemiology of United States-2029

    6.2. Epidemiology of United Kingdom-2029

    6.3. Epidemiology of Germany-2029

    6.4. Epidemiology of France-2029

    6.5. Epidemiology of Spain-2029

    6.6. Epidemiology of Italy-2029

    6.7. Epidemiology of Japan-2029

    6.8. Epidemiology of Emerging Markets-2029

    7. Global Market size (2018-2029)

    7.1. Global Forecasted Market size (2018-2029)

    7.2. Global Market Size by Geography

    7.2.1. Market size of US (2014-2018)

    7.2.2. Forecasted Market size of US (2018-2029)

    7.2.3. Market size of Europe

    7.2.4. Market size of Germany (2014-2018)

    7.2.5. Forecasted Market size of Germany (2018-2029)

    7.2.6. Market size of United Kingdom (2014-2018)

    7.2.7. Forecasted Market size of United Kingdom (2018-2029)

    7.2.8. Market size of France (2014-2018)

    7.2.9. Forecasted Market size of France (2018-2029)

    7.2.10. Market size of Italy (2014-2018)

    7.2.11. Forecasted Market size of Italy (2018-2029)

    7.2.12. Market size of Spain (2014-2018)

    7.2.13. Forecasted Market size of Spain (2018-2029)

    7.2.14. Market size of Japan (2014-2018)

    7.2.15. Forecasted Market Size of Japan (2018-2029)

    7.2.16. Market size of Emerging Markets (2014-2018)

    7.2.17. Forecasted Market size of Emerging Markets (2018-2029)

    8. Market Trends

    9. Market Opportunity Assessment

    10. Drivers and Barriers

    11. Unmet Needs

    12. SWOT Analysis

    13. Appendix

    14. Report Methodology

    15. Consulting Services

    16.Disclaimer

List Of Tables
in Metastatic Liver Cancer - Market Review, Epidemiology And Market Forecast - 2029 [Published by First View Insight]

Table 1: Incident Cases of Metastatic Liver Cancer in United States (2018-2029)

Table 2: List of Phase III Drugs for 29

Table 3: Drug 1Clinical Trials by Zone, 2019

Table 4: Drug 2 Clinical Trials by Zone, 2019

Table 5: Drug 1 Clinical Trials by Zone, 2019

Table 6: Drug 2Clinical Trials by Zone, 2019

Table 7: Drug 1Clinical Trials by Zone, 2019

Table 8: Drug 2Clinical Trials by Zone, 2019

Table 9: Drug 1Clinical Trials by Zone, 2019

Table 10: Drug 2Clinical Trials by Zone, 2019

Table 11: United States Market Size of in USD, Million (2018-2029)

List Of Figures, Charts and Diagrams
in Metastatic Liver Cancer - Market Review, Epidemiology And Market Forecast - 2029 [Published by First View Insight]

Figure 1: Pathophysiology for Metastatic Liver Cancer

Figure 2: Risk Factors for Metastatic Liver Cancer

Figure 3: Etiology of Metastatic Liver Cancer

Figure 4: Incident Probable Cases of in United States (2018-2029)Figure 5: Treatment Algorithm

Figure 6: Lines of Treatment

Figure 7: Incident Cases of Metastatic Liver Cancer in United States (2018-2029)

Figure 8: List of Phase III Drugs for Metastatic Liver Cancer

Figure 9: Drug 1Clinical Trials by Zone, 2019

Figure 10: Drug 2 Clinical Trials by Zone, 2019

Figure 11: Drug 1 Clinical Trials by Zone, 2019

Figure 12: Drug 2Clinical Trials by Zone, 2019

Figure 13: Drug 1Clinical Trials by Zone, 2019

Figure 14: Drug 2Clinical Trials by Zone, 2019

Figure 15: Drug 1Clinical Trials by Zone, 2019

Figure 16: Drug 2Clinical Trials by Zone, 2019

Figure 17: United States Market Size of in USD, Million (2018-2029)

Additional Details

Publisher

First View Insight

Publisher Information

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.



About FirstView Insight



FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Reference

241399 |

Number of Pages

200

Report Format

PDF

First View Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by First View Insight

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.

About FirstView Insight

FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Download Free Report Summary PDF

Metastatic Liver Cancer  - Market Review, Epidemiology And Market Forecast - 2029 [Published by First View Insight] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...